Early versus deferred antiretroviral therapy in children in low-income and middle-income countries

Current Opinion in HIV and AIDS

Volumn 5, Issue 1, 2010, Pages 12-17

  Puthanakit, Thanyawee ^a,b   Bunupuradah, Torsak ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

Antiretroviral therapy; Children; Early treatment; HIV; Infants; Resource limited settings

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILDHOOD DISEASE; CLINICAL TRIAL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE COURSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT MORTALITY; INFECTION RISK; LIPODYSTROPHY; MEDICAL PERSONNEL; MEDICAL STAFF; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE DRUG DOSE; SKILL; TREATMENT INDICATION; TREATMENT WITHDRAWAL; VERTICAL TRANSMISSION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ADULT; AFRICA; ANTI-HIV AGENTS; ASIA; CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; POVERTY; PRACTICE GUIDELINES AS TOPIC;

EID: 74349115239     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283339b27     Document Type: Review

References (44)

1. Lowrance DW, Makombe S, Harries AD, et al. A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. J Acquir Immune Defic Syndr 2008; 49:287-293.
2. Bendavid E, Bhattacharya J. The President's Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes. Ann Inter Med 2009; 150:688-695.
3. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8:477-489.
4. Kiboneka A, Wangisi J, Nabiryo C, et al. Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. AIDS 2008; 22:2493-2499.
5. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis 2005; 41:100-107.
6. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 44:599-604. (Pubitemid 46233267)
7. Zhang F, Haberer JE, Zhao Y, et al. Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes. J Acquir Immune Defic Syndr 2007; 46:594-598.
8. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics 2007; 120:e1134-e1140.
9. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. http://www.pentatrials.org/guide09.pdf. Accessed 31 July 2009
10. Working Group on Antiretroviral Therapy and Medical Management of HIVInfected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Department of Health and Human Services. Updated 23 February 2009. http://www.aidsinfo.nih.gov/ContentFiles/pediatricGuidelines. pdf. Accessed 31 July 2009
11. World Health Organization. WHO antiretroviral therapy for infants and children. Geneva, Switzerland: WHO; 2008. http://www.who.int/hiv/pub/paediatric/ WHO-Paediatric-ART-guideline-rev-mreport-2008.pdf. Accessed 31 July 2009
12. Natural history of vertically acquired human immunodeficiency virus-1 infection. The European Collaborative Study. Pediatrics 1994; 94(6 Pt 1):815-819.
13. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-1243.
14. Mphatswe W, Blanckenberg N, Tudor-Williams G, et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS 2007; 21:1253-1261.
15. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. New Engl J Med 2008; 359:2233-2244.
16. Laughton B, Grove D, Kidd M, et al. Early antiretroviral therapy is associated with improved neurodevelopmental outcome in HIV infected infants; evidence from the CHER (Children with HIV Early Antiretroviral Therapy) trial. (abstract O-07). Rev Antiviral Ther 2009; 6:8-9.
17. Goetghebuer T, Haelterman E, Le Chenadec J, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009; 23:597-604.
18. Hobbs CV, Essajee SM. Early treatment of HIV: implications for resourcelimited settings. Curr Opin HIV AIDS 2009; 4:222-231.
19. Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V. Efficacy of nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less. Pediatr Infect Dis J 2009; 28:246-248.
20. Ngo-Giang-Huong N, Khamduang W, Leurent B, et al. Early HIV-1 diagnosis using in-house real-time PCR amplification on dried blood spots for infants in remote and resource-limited settings. J Acquir Immune Defic Syndr 2008; 49:465-471.
21. Creek T, Tanuri A, Smith M, et al. Early diagnosis of human immunodeficiency virus in infants using polymerase chain reaction on dried blood spots in Botswana's national program for prevention of mother-to-child transmission. Pediatr Infect Dis J 2008; 27:22-26.
22. Rollins N, Mzolo S, Moodley T, et al. Universal HIV testing of infants at immunization clinics: an acceptable and feasible approach for early infant diagnosis in high HIV prevalence settings. AIDS 2009; 23:1851-1857.
23. Kankasa C, Carter RJ, Briggs N, et al. Routine offering of HIV testing to hospitalized pediatric patients at university teaching hospital, Lusaka, Zambia: acceptability and feasibility. J Acquir Immune Defic Syndr 2009; 51:202-208.
24. van Griensven J, De Naeyer L, Uwera J, et al. Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/nursebased care. BMC Pediatr 2008; 8:39.
25. Peltier CA, Omes C, Ndimubanzi PC, et al. Validation of 2006 WHO prediction scores for true HIV infection in children less than 18 months with a positive serological HIV test. PloS ONE 2009; 4:e5312.
26. Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T, et al. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV. Clin Infect Dis 2009; 49:299-305.
27. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-1021.
28. Palumbo P, Violari A, Lindsey J, et al., IMPAACT P1060 team Nevirapine(NVP) vs lopinavir-ritonavir (LPV/r)-based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial. (abstract LBPEB12). In Program and Abstract of the 5th Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
29. Coovadia A, Abrams E, Strehlau R, et al., NEVEREST Study team. Randomized clinical trial of switching to nevirapine-based therapy for infected children exposed to nevirapine prophylaxis (abstract MOAB1). In Program and Abstract of the 5th Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
30. Chadwick EG, Capparelli EV, Yogev R, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS 2008; 22:249-255.
31. Markers for predicting mortality in untreated HIV-infected children in resourcelimited settings: a meta-analysis. AIDS 2008; 22:97-105.
32. Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the shortterm risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008; 197:398-404.
33. Welch SB, Gibb D. When should children with HIV infection be started on antiretroviral therapy? PLoS Med 2008; 5:e73.
34. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144.
35. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
36. Starting Antiretroviral Therapy Earlier Yields Better Clinical Outcomes. http:// www3.niaid.nih.gov/news/newsreleases/2009/CIPRA-HT-01.htm. Accessed on 14 August 2009
37. Puthanakit T, Kerr S, Ananworanich J, et al. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J 2009; 28:488-492.
38. Patel K, Hernan MA, Williams PL, et al. Long-term effects of highly active antiretroviral therapy on CD4p cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis 2008; 46:1751-1760.
39. Kekitiinwa A, Lee KJ, Walker AS, et al. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr 2008; 49:384-392.
40. Aurpibul L, Puthanakit T, Lee B, et al. Lipodystrophy and metabolic changes in HIV-infected children on nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antiviral Ther 2007; 12:1247-1254.
41. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V. Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J 2009; 28:826-830.
42. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46:187-193.
43. Kumarasamy N, Madhavan V, Venkatesh KK, et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis 2009; 49:306-309.
44. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-452